Real-world outcomes of TMVR-eligible and TMVR-ineligible patients

Background Over the past decade, transcatheter valve replacement has emerged as a therapy for selected patients with valvular heart. . Clinical experience with transcatheter mitral valve replacement (TMVR) has been limited to date and provides little insight into its potential as a viable therapy for MR6,7. The present study aims to analyze the current longest follow-up real-life outcomes of TMVR procedures with a specific focus on the patient population left untreated due to the unfeasibility of the procedure. Objectives The present study aims to analyze the current longest follow-up real-life outcomes of TMVR procedures with a specific focus on the patient population left untreated due to the unfeasibility of the procedure. Results Out of 3400 patients referred for mitral pathology, 88 were screened for TMVR procedure, being unfeasible for surgical and TEER procedure (Transcatheter Edge-to-Edge Repair). 37 pts (45%) were screened positive and treated with TMVR; 30 (81%) with Tendyne system (Abbott) and 7 (19 %) with Tiara. For cardiac death, in TMVR the survival was 97,2%, 90,7% and 90,7% at 1, 2, and 4 years, respectively. Concerning MT, instead, it was 86,4%, 77% and 42% at 1, 2, and 4 years, respectively. A difference is seen between the two groups, p-value 0.024. Conclusions TMVR is a valid option in selected patients and give valid longer follow up results. The TMVR ineligible patients showed a progressive detrimental worse survival across the follow-up.